An association between genetic variations in the glucagon-like peptide 1 (GLP-1) analogue target and a lower risk of AD was also observed (OR = 0.32 per 1 mmol/L decrement in blood glucose, 95% CI 0.13–0.79, p = 0.014). This evidence concerns the gene GLP1R and Alzheimer disease.